Compare CCIF & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CCIF | PLRX |
|---|---|---|
| Founded | 2011 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 67.7M | 70.6M |
| IPO Year | N/A | 2020 |
| Metric | CCIF | PLRX |
|---|---|---|
| Price | $2.82 | $1.15 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $2.67 |
| AVG Volume (30 Days) | 117.4K | ★ 354.6K |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | ★ 25.90% | N/A |
| EPS Growth | N/A | ★ 29.97 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.57 | $1.09 |
| 52 Week High | $6.59 | $1.95 |
| Indicator | CCIF | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 36.72 | 51.01 |
| Support Level | $2.57 | $1.13 |
| Resistance Level | $3.45 | $1.37 |
| Average True Range (ATR) | 0.11 | 0.04 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 40.32 | 68.42 |
Carlyle Credit Income Fund is a non-diversified, closed-end management investment company. The Fund's primary investment objective is to generate current income, with a secondary objective to generate capital appreciation. The Fund seeks to achieve its investment objective by investing predominantly in equity and junior debt tranches of collateralized loan obligations, that are collateralized by a portfolio consisting mainly of below-investment-grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.